Cellebrite DI (NASDAQ:CLBT) Price Target Lowered to $16.00 at JPMorgan Chase & Co.

Cellebrite DI (NASDAQ:CLBT) had its target price decreased by investment analysts at JPMorgan Chase & Co. from $20.00 to $16.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 45.79% from the stock’s current price.

Several other equities analysts also recently commented on the company. Needham & Company LLC cut their price objective on Cellebrite DI from $15.00 to $12.50 and set a “buy” rating on the stock in a research report on Friday. DA Davidson cut their price target on shares of Cellebrite DI from $22.00 to $15.00 and set a “buy” rating on the stock in a report on Friday. Finally, Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $18.30.

Cellebrite DI Price Performance

Shares of CLBT traded up $0.17 during midday trading on Friday, hitting $10.97. The stock had a trading volume of 4,049,603 shares, compared to its average volume of 2,117,300. The stock’s 50 day moving average is $14.52 and its 200 day moving average is $14.05. The firm has a market cap of $2.74 billion, a PE ratio of 39.19, a price-to-earnings-growth ratio of 1.89 and a beta of 1.18. Cellebrite DI has a 1 year low of $9.58 and a 1 year high of $19.98.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings results on Thursday, August 13th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.05 by $0.06. Cellebrite DI had a net margin of 14.48% and a return on equity of 18.38%. The company had revenue of $131.14 million for the quarter, compared to the consensus estimate of $131.87 million. As a group, equities research analysts expect that Cellebrite DI will post 0.41 earnings per share for the current fiscal year.

Insider Activity

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $12.77, for a total value of $161,642.66. Following the transaction, the executive owned 440,101 shares in the company, valued at $5,620,089.77. The trade was a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO David Barter sold 41,734 shares of Cellebrite DI stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total transaction of $683,602.92. Following the completion of the transaction, the chief financial officer directly owned 334,219 shares in the company, valued at approximately $5,474,507.22. The trade was a 11.10% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 297,934 shares of company stock worth $4,631,972. Corporate insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Cellebrite DI

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Voss Capital LP increased its position in shares of Cellebrite DI by 18.9% in the 4th quarter. Voss Capital LP now owns 8,050,000 shares of the company’s stock valued at $145,142,000 after acquiring an additional 1,277,300 shares during the period. Pertento Partners LLP increased its holdings in Cellebrite DI by 28.2% in the 4th quarter. Pertento Partners LLP now owns 5,959,324 shares of the company’s stock worth $107,447,000 after buying an additional 1,311,109 shares during the period. Invesco Ltd. lifted its stake in Cellebrite DI by 0.8% during the 4th quarter. Invesco Ltd. now owns 5,603,237 shares of the company’s stock valued at $101,026,000 after acquiring an additional 43,041 shares during the period. Granahan Investment Management LLC increased its stake in shares of Cellebrite DI by 16.3% in the fourth quarter. Granahan Investment Management LLC now owns 3,057,018 shares of the company’s stock worth $55,118,000 after acquiring an additional 427,719 shares during the period. Finally, Cooper Creek Partners Management LLC acquired a new position in Cellebrite DI during the third quarter valued at $55,999,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Cellebrite DI News Summary

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Cellebrite reported adjusted second-quarter EPS of $0.11, ahead of the $0.05 consensus cited by MarketBeat. Subscription revenue continued to grow, and management raised its adjusted EBITDA target. Cellebrite earnings and outlook announcement
• Positive Sentiment: DA Davidson and Needham retained Buy ratings, with their revised price targets of $15 and $12.50 respectively still implying potential upside from recent levels. Analyst price target updates
• Neutral Sentiment: Nearly 20,000 CLBT call options traded, far above typical volume. The activity may indicate some traders expect a rebound, but options positioning is speculative and does not change the company’s fundamentals.
• Neutral Sentiment: Cellebrite named Shiven Ramji as CEO, succeeding Thomas E. Hogan in a planned transition. The change could support a strategic reset, but leadership turnover adds uncertainty during a period of weaker growth. CEO transition announcement
• Negative Sentiment: Revenue of $131.14 million slightly missed estimates, while analysts highlighted an annual recurring revenue shortfall. More importantly, third-quarter revenue guidance of $145 million-$148 million and full-year guidance of $555 million-$561 million were below consensus expectations of $150.3 million and $568.1 million. The company also lowered its full-year ARR outlook. Cellebrite guidance report
• Negative Sentiment: Several law firms announced investigations into possible securities-law violations and whether Cellebrite’s earlier projections and disclosures were accurate. These are allegations, not established findings, but they increase legal and reputational risk. Cellebrite investigation notice
• Negative Sentiment: CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, reducing his holdings by about 15%. While the sale may reflect personal planning or the CEO transition, its timing is a negative sentiment factor. SEC insider sale filing

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.